NCT00363974View on ClinicalTrials.gov

Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Leukemia, Myelomonocytic, Acute
Interventions
DRUG

XIAP antisense

2 days loading dose followed by weekly 2hr infusion

Trial Locations (7)

21231

Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore

60611

Northwestern Memorial Hospital, Chicago

90033

Norris Cancer Center - University of Southern California, Los Angeles

90095

UCLA Medical Center, Los Angeles

77030-4009

M.D. Anderson Cancer Center, Houston

M5G 2M9

Princess Margaret Hospital, Toronto

Unknown

Hopital Maisonneuve-Rosemont, Montreal

Sponsors
All Listed Sponsors
lead

Aegera Therapeutics

INDUSTRY

NCT00363974 - Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML | Biotech Hunter | Biotech Hunter